Covid-19 roundup: Mod­er­na kicks off tri­al for Omi­cron-spe­cif­ic vac­cine; EMA signs off on Pfiz­er pill

Just a day af­ter Pfiz­er and BioN­Tech an­nounced the start of tri­als for their Omi­cron-spe­cif­ic vac­cine boost­er can­di­date, Mod­er­na put out word that it too has be­gun test­ing an up­dat­ed vac­cine de­signed to tar­get the vari­ant.

The can­di­date, dubbed mR­NA-1273.529, will be ad­min­is­tered to two dif­fer­ent co­horts of par­tic­i­pants in a Phase II study: par­tic­i­pants who on­ly re­ceived the two-dose pri­ma­ry se­ries of mR­NA-1273, and par­tic­i­pants who re­ceived both the two-dose reg­i­men and a 50 µg boost­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER